FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947156614> ?p ?o ?g. }

• W2947156614 abstract "Abstract Background Myeloid-derived suppressor cells (MDSCs) are elevated in glioblastoma (GBM) patient circulation, present in tumor tissue, and associated with poor prognosis. While low-dose chemotherapy reduces MDSCs in preclinical models, the use of this strategy to reduce MDSCs in GBM patients has yet to be evaluated. Methods A phase 0/1 dose-escalation clinical trial was conducted in recurrent glioblastoma patients treated 5-7 days prior to surgery with low-dose chemotherapy via capecitabine followed by concomitant low-dose capecitabine and bevacizumab. Clinical outcomes, including progression-free and overall survival, were measured, along with safety and toxicity profiles. Over the treatment time course, circulating MDSC levels were measured by multi-parameter flow cytometry, and tumor tissue immune profiles were assessed via mass cytometry time-of-flight. Results A total of 11 patients were enrolled across escalating dose cohorts of 150, 300, and 450 mg bid, with a progression-free survival of 5.8 months (range of 1.8-27.8 months) and an overall survival of 11.5 months (range of 3->28.0 months) from trial enrollment. No serious adverse events related to the drug combination were observed. Compared to pre-treatment baseline, circulating MDSCs were found to be higher after surgery in the 150 mg treatment arm and lower in the 300 mg and 450 mg treatment arms. Increased cytotoxic immune infiltration was observed after low-dose capecitabine compared to untreated GBM patients in the 300 mg and 450 mg treatment arms. Conclusions Low-dose, metronomic capecitabine in combination with bevacizumab is well tolerated in GBM patients and was associated with a reduction in circulating MDSC levels and an increase in cytotoxic immune infiltration into the tumor microenvironment. Trial registration NCT02669173 Funding This research was funded by the Cleveland Clinic, Case Comprehensive Cancer Center, Musella Foundation, and B*CURED. Capecitabine was provided in kind by Mylan Pharmaceuticals." @default.
• W2947156614 created "2019-06-07" @default.
• W2947156614 creator A5003172017 @default.
• W2947156614 creator A5004589257 @default.
• W2947156614 creator A5005615879 @default.
• W2947156614 creator A5007126068 @default.
• W2947156614 creator A5008954779 @default.
• W2947156614 creator A5011290782 @default.
• W2947156614 creator A5021893710 @default.
• W2947156614 creator A5035416012 @default.
• W2947156614 creator A5039448543 @default.
• W2947156614 creator A5045015097 @default.
• W2947156614 creator A5055822465 @default.
• W2947156614 creator A5062310885 @default.
• W2947156614 creator A5067549660 @default.
• W2947156614 creator A5075490964 @default.
• W2947156614 date "2019-05-31" @default.
• W2947156614 modified "2023-09-23" @default.
• W2947156614 title "Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells" @default.
• W2947156614 cites W1886553715 @default.
• W2947156614 cites W1974254625 @default.
• W2947156614 cites W2022380404 @default.
• W2947156614 cites W2031352878 @default.
• W2947156614 cites W2035404015 @default.
• W2947156614 cites W2038426170 @default.
• W2947156614 cites W2062601742 @default.
• W2947156614 cites W2068934982 @default.
• W2947156614 cites W2076991947 @default.
• W2947156614 cites W2079068389 @default.
• W2947156614 cites W2100891433 @default.
• W2947156614 cites W2115961668 @default.
• W2947156614 cites W2117728670 @default.
• W2947156614 cites W2124736921 @default.
• W2947156614 cites W2133496985 @default.
• W2947156614 cites W2142378149 @default.
• W2947156614 cites W2144418568 @default.
• W2947156614 cites W2152677909 @default.
• W2947156614 cites W2158681922 @default.
• W2947156614 cites W2159840059 @default.
• W2947156614 cites W2164675211 @default.
• W2947156614 cites W2166662937 @default.
• W2947156614 cites W2253972308 @default.
• W2947156614 cites W2266683146 @default.
• W2947156614 cites W2306651097 @default.
• W2947156614 cites W2346941018 @default.
• W2947156614 cites W2471500324 @default.
• W2947156614 cites W2528955564 @default.
• W2947156614 cites W2615491662 @default.
• W2947156614 cites W2764040657 @default.
• W2947156614 cites W2768388636 @default.
• W2947156614 cites W2796584001 @default.
• W2947156614 cites W2808979164 @default.
• W2947156614 cites W2889103878 @default.
• W2947156614 cites W2896013175 @default.
• W2947156614 cites W2908723963 @default.
• W2947156614 cites W2911752971 @default.
• W2947156614 cites W2911871569 @default.
• W2947156614 cites W2913623258 @default.
• W2947156614 cites W2914199948 @default.
• W2947156614 cites W2932567234 @default.
• W2947156614 cites W4234865248 @default.
• W2947156614 cites W4240098044 @default.
• W2947156614 cites W4248371100 @default.
• W2947156614 doi "https://doi.org/10.1101/655688" @default.
• W2947156614 hasPublicationYear "2019" @default.
• W2947156614 type Work @default.
• W2947156614 sameAs 2947156614 @default.
• W2947156614 citedByCount "0" @default.
• W2947156614 crossrefType "posted-content" @default.
• W2947156614 hasAuthorship W2947156614A5003172017 @default.
• W2947156614 hasAuthorship W2947156614A5004589257 @default.
• W2947156614 hasAuthorship W2947156614A5005615879 @default.
• W2947156614 hasAuthorship W2947156614A5007126068 @default.
• W2947156614 hasAuthorship W2947156614A5008954779 @default.
• W2947156614 hasAuthorship W2947156614A5011290782 @default.
• W2947156614 hasAuthorship W2947156614A5021893710 @default.
• W2947156614 hasAuthorship W2947156614A5035416012 @default.
• W2947156614 hasAuthorship W2947156614A5039448543 @default.
• W2947156614 hasAuthorship W2947156614A5045015097 @default.
• W2947156614 hasAuthorship W2947156614A5055822465 @default.
• W2947156614 hasAuthorship W2947156614A5062310885 @default.
• W2947156614 hasAuthorship W2947156614A5067549660 @default.
• W2947156614 hasAuthorship W2947156614A5075490964 @default.
• W2947156614 hasBestOaLocation W29471566141 @default.
• W2947156614 hasConcept C121608353 @default.
• W2947156614 hasConcept C126322002 @default.
• W2947156614 hasConcept C143998085 @default.
• W2947156614 hasConcept C197934379 @default.
• W2947156614 hasConcept C203014093 @default.
• W2947156614 hasConcept C2776694085 @default.
• W2947156614 hasConcept C2777802072 @default.
• W2947156614 hasConcept C2777909004 @default.
• W2947156614 hasConcept C2779384505 @default.
• W2947156614 hasConcept C29730261 @default.
• W2947156614 hasConcept C526805850 @default.
• W2947156614 hasConcept C71924100 @default.
• W2947156614 hasConcept C8891405 @default.
• W2947156614 hasConcept C90924648 @default.
• W2947156614 hasConceptScore W2947156614C121608353 @default.
• W2947156614 hasConceptScore W2947156614C126322002 @default.

• next